Selinexor With Lower-Dose Radiation for Early Nasal Lymphoma
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug called selinexor combined with lower doses of radiation therapy for patients with a rare type of lymphoma (NK/T-cell lymphoma) that starts in the nose or upper throat. The goal is to improve how well the cancer responds to treatment while reducing radiation side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with extranodal NK/T-cell lymphoma (ENKTCL), a rare type of blood cancer, confirmed by a tissue biopsy
- Your cancer is in an early stage (Ann Arbor stage I-II) and located in the nasal cavity or upper throat area
- You have not received any prior chemotherapy, radiation therapy, or targeted cancer drugs
- Your blood counts, liver, kidney, and heart function are adequate based on recent lab tests
- You are between 18 and 75 years old and in generally good health (ECOG performance status 0-2)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether sugemalimab (or a placebo) added to a chemotherapy plan can better control extranodal NK/T-cell lymphoma that has come back or didn’t respond to previous treatment. It may help patients by improving the chance of shrinking the tumor and extending how long the disease stays under control.
This Phase 2 study tests whether a medicine called selinexor, combined with COPL, can shrink newly diagnosed NK/T-cell lymphoma that is advanced (stage III–IV). It also looks at how safely the treatment works in people who have good enough blood counts and organ function.
This trial tests a combination of three drugs (selinexor, pegaspargase, and dexamethasone) for people with newly diagnosed NK/T-cell lymphoma. It aims to see if this treatment can shrink tumors and be safe.
This trial tests a combination of three drugs—selinexor, an anti-PD-1 antibody (immune therapy), and golidocitinib—for people with NK/T-cell lymphoma that has come back or not responded to prior treatment. The goal is to see if this new combination can shrink tumors and help patients live longer.
This study tests a combination of three drugs (sintilimab, pegaspargase, and selinexor) followed by radiation therapy for newly diagnosed extranodal NK/T-cell lymphoma, a rare type of blood cancer. The goal is to see if this combination can help control the cancer better than standard treatment alone.
This study tests a new combination of three drugs (selinexor, an anti-PD-1 antibody, and a chemotherapy regimen called P-GemOx) for people with NKT-cell lymphoma that has come back or not responded to prior treatment. The goal is to see if this combination works better than current options.
Hear when a new Extranodal NK/T-cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.